New treatment approach for difficult-to-surgically-remove pancreatic cancer
Total Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
This study is looking at a new way to treat patients with tough-to-reach pancreatic cancer by giving them chemotherapy and radiation before surgery to help shrink the tumors and make surgery more successful.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10908415 on NIH RePORTER |
What this research studies
This research investigates a new treatment strategy called total neoadjuvant therapy (TNT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma. The approach involves administering a combination of chemotherapy and radiotherapy before surgery to shrink tumors and improve surgical outcomes. By evaluating the effectiveness of a specific chemotherapy regimen, the study aims to identify which patients are most likely to benefit from surgery and to personalize treatment plans based on individual responses. This comprehensive evaluation seeks to enhance the chances of successful tumor removal and improve overall patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with borderline resectable or locally advanced pancreatic adenocarcinoma who have not yet undergone surgery.
Not a fit: Patients with early-stage pancreatic cancer who are already eligible for surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase the number of patients eligible for curative surgery and improve survival rates for those with advanced pancreatic cancer.
How similar studies have performed: Previous research has shown promising results with neoadjuvant therapy approaches in similar patient populations, indicating potential for success with this novel treatment strategy.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Wei, Alice Chia- Chi — Sloan-Kettering Inst Can Research
- Study coordinator: Wei, Alice Chia- Chi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.